Search research articles
Contact Us
Filters
Showing results (21-30 of 47) with videos related to
Page
of 5
Sort By:
Cancer Cell
|
April 22, 2014
Disruption of CRAF-mediated MEK activation is required for effective MEK inhibition in KRAS mutant tumors
Piro Lito, Anna Saborowski, Jingyin Yue, et al.
Clinical Cancer Research : an Official Journal of the American Association for Cancer Research
|
February 9, 2021
Treatment Outcomes and Clinical Characteristics of Patients with KRAS-G12C-Mutant Non-Small Cell Lung Cancer
Kathryn C Arbour, Hira Rizvi, Andrew J Plodkowski, et al.
JCO Precision Oncology
|
June 29, 2023
Clinical and Genomic Features of Response and Toxicity to Sotorasib in a Real-World Cohort of Patients With Advanced <i>KRAS G12C</i>-Mutant Non-Small Cell Lung Cancer
Rohit Thummalapalli, Ezra Bernstein, Benjamin Herzberg, et al.
Cancer Cell
|
November 17, 2012
Relief of profound feedback inhibition of mitogenic signaling by RAF inhibitors attenuates their activity in BRAFV600E melanomas
Piro Lito, Christine A Pratilas, Eric W Joseph, et al.
Clinical Cancer Research : an Official Journal of the American Association for Cancer Research
|
November 2, 2017
Effects of Co-occurring Genomic Alterations on Outcomes in Patients with <i>KRAS</i>-Mutant Non-Small Cell Lung Cancer
Kathryn C Arbour, Emmett Jordan, Hyunjae Ryan Kim, et al.
Biorxiv : the Preprint Server for Biology
|
July 14, 2025
BRAF<sup>V600E</sup>-Driven Lung Tumorigenesis Requires Ligand-Mediated Activation of ERBB Receptor Signaling
Melanie Angelina Dacheux, Meng-Jung Wu, Michael T Scherzer, et al.
JTO Clinical and Research Reports
|
January 5, 2022
Phase 1 Clinical Trial of Trametinib and Ponatinib in Patients With NSCLC Harboring <i>KRAS</i> Mutations
Kathryn C Arbour, Eusebio Manchado, Matthew J Bott, et al.
Clinical Lung Cancer
|
February 23, 2016
Large Cell Neuroendocrine Carcinoma of the Lung: Clinico-Pathologic Features, Treatment, and Outcomes
Jarushka Naidoo, Maria L Santos-Zabala, Tunc Iyriboz, et al.
Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology
|
April 25, 2023
Long-Term Outcomes and Molecular Correlates of Sotorasib Efficacy in Patients With Pretreated <i>KRAS</i> G12C-Mutated Non-Small-Cell Lung Cancer: 2-Year Analysis of CodeBreaK 100
Grace K Dy, Ramaswamy Govindan, Vamsidhar Velcheti, et al.
Future Oncology (London, England)
|
November 27, 2023
Long-term benefit of sotorasib in patients with KRAS G12C-mutated non-small-cell lung cancer: plain language summary
Grace K Dy, Ramaswamy Govindan, Vamsidhar Velcheti, et al.
Page
of 5
Search research articles
Search
Showing results (21-30 of 47) with videos related to
Sort By:
Page
of 5
Cancer Cell
|
April 22, 2014
Disruption of CRAF-mediated MEK activation is required for effective MEK inhibition in KRAS mutant tumors
Piro Lito, Anna Saborowski, Jingyin Yue, et al.
Clinical Cancer Research : an Official Journal of the American Association for Cancer Research
|
February 9, 2021
Treatment Outcomes and Clinical Characteristics of Patients with KRAS-G12C-Mutant Non-Small Cell Lung Cancer
Kathryn C Arbour, Hira Rizvi, Andrew J Plodkowski, et al.
JCO Precision Oncology
|
June 29, 2023
Clinical and Genomic Features of Response and Toxicity to Sotorasib in a Real-World Cohort of Patients With Advanced <i>KRAS G12C</i>-Mutant Non-Small Cell Lung Cancer
Rohit Thummalapalli, Ezra Bernstein, Benjamin Herzberg, et al.
Cancer Cell
|
November 17, 2012
Relief of profound feedback inhibition of mitogenic signaling by RAF inhibitors attenuates their activity in BRAFV600E melanomas
Piro Lito, Christine A Pratilas, Eric W Joseph, et al.
Clinical Cancer Research : an Official Journal of the American Association for Cancer Research
|
November 2, 2017
Effects of Co-occurring Genomic Alterations on Outcomes in Patients with <i>KRAS</i>-Mutant Non-Small Cell Lung Cancer
Kathryn C Arbour, Emmett Jordan, Hyunjae Ryan Kim, et al.
Biorxiv : the Preprint Server for Biology
|
July 14, 2025
BRAF<sup>V600E</sup>-Driven Lung Tumorigenesis Requires Ligand-Mediated Activation of ERBB Receptor Signaling
Melanie Angelina Dacheux, Meng-Jung Wu, Michael T Scherzer, et al.
JTO Clinical and Research Reports
|
January 5, 2022
Phase 1 Clinical Trial of Trametinib and Ponatinib in Patients With NSCLC Harboring <i>KRAS</i> Mutations
Kathryn C Arbour, Eusebio Manchado, Matthew J Bott, et al.
Clinical Lung Cancer
|
February 23, 2016
Large Cell Neuroendocrine Carcinoma of the Lung: Clinico-Pathologic Features, Treatment, and Outcomes
Jarushka Naidoo, Maria L Santos-Zabala, Tunc Iyriboz, et al.
Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology
|
April 25, 2023
Long-Term Outcomes and Molecular Correlates of Sotorasib Efficacy in Patients With Pretreated <i>KRAS</i> G12C-Mutated Non-Small-Cell Lung Cancer: 2-Year Analysis of CodeBreaK 100
Grace K Dy, Ramaswamy Govindan, Vamsidhar Velcheti, et al.
Future Oncology (London, England)
|
November 27, 2023
Long-term benefit of sotorasib in patients with KRAS G12C-mutated non-small-cell lung cancer: plain language summary
Grace K Dy, Ramaswamy Govindan, Vamsidhar Velcheti, et al.
Page
of 5